Needham & Company Maintains a 'Hold' on Hi Tech Pharmacal (HITK); Q4 Mixed; Flonase Beginning To Show Its Age
Tweet Send to a FriendGet Alerts HITK Hot Sheet
Price: $33.91 +3.38%
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 1 | New: 1
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 1 | New: 1
Trade HITK Now!
Needham & Company maintains a 'Hold' on Hi Tech Pharmacal (NASDAQ: HITK).
Analyst, Elliot Wilbur, said, "Despite another very strong generic Flonase quarter enabling HITK to easily outpace top-line expectations, 4QF12 EPS came up short of our numbers owing to light gross margin and accelerated investment spend. While signs of imminent new competition on generic Flonase remain few and far between, 4QF12 sales almost certainly represented a peak quarter both on an absolute and relative basis and while our assumption of an 11% y/y decline in Flonase sales appears reasonable, we remain concerned about the possibility of downside surprises to our EPS forecast given accelerated investment spend both in SG&A and R&D, implying little P&L “give” for negative top-line variances. Though shares resiliently shook off another soft quarter, they are likely to remain highly captive to any and all generic Flonase developments for the foreseeable future."
FY13 EPS estimate cut from $3.63 to $3.32 and FY14 from $3.71 to $3.68.
For an analyst ratings summary and ratings history on Hi Tech Pharmacal click here. For more ratings news on Hi Tech Pharmacal click here.
Shares of Hi Tech Pharmacal closed at $29.97 yesterday, with a 52 week range of $23.72-$44.58.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Elliot Wilbur, said, "Despite another very strong generic Flonase quarter enabling HITK to easily outpace top-line expectations, 4QF12 EPS came up short of our numbers owing to light gross margin and accelerated investment spend. While signs of imminent new competition on generic Flonase remain few and far between, 4QF12 sales almost certainly represented a peak quarter both on an absolute and relative basis and while our assumption of an 11% y/y decline in Flonase sales appears reasonable, we remain concerned about the possibility of downside surprises to our EPS forecast given accelerated investment spend both in SG&A and R&D, implying little P&L “give” for negative top-line variances. Though shares resiliently shook off another soft quarter, they are likely to remain highly captive to any and all generic Flonase developments for the foreseeable future."
FY13 EPS estimate cut from $3.63 to $3.32 and FY14 from $3.71 to $3.68.
For an analyst ratings summary and ratings history on Hi Tech Pharmacal click here. For more ratings news on Hi Tech Pharmacal click here.
Shares of Hi Tech Pharmacal closed at $29.97 yesterday, with a 52 week range of $23.72-$44.58.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- Deutsche Bank Sees Upside in AIG (AIG) Stock
- Wells Fargo Starts Quintiles (Q) at Outperform
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS ViewRelated Entities
Needham & Company
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
